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Abstract
Background: Osteoblasts and adipocytes are derived from a common mesenchymal progenitor and an inverse
relationship between expression of the two lineages is seen with certain experimental manipulations and in certain
diseases, i.e., osteoporosis, but the cellular pathway(s) and developmental stages underlying the inverse
relationship is still under active investigation. To determine which precursor mesenchymal cell types can
differentiate into adipocytes, we compared the effects of BRL-49653 (BRL), a selective ligand for peroxisome
proliferators-activated receptor (PPAR)γ, a master transcription factor of adipogenesis, on osteo/adipogeneis in
two different osteoblast culture models: the rat bone marrow (RBM) versus the fetal rat calvaria (RC) cell system.
Results: BRL increased the number of adipocytes and corresponding marker expression, such as lipoprotein
lipase, fatty acid-binding protein (aP2), and adipsin, in both culture models, but affected osteoblastogenesis only
in RBM cultures, where a reciprocal decrease in bone nodule formation and osteoblast markers, e.g., osteopontin,
alkaline phosphatase (ALP), bone sialoprotein, and osteocalcin was seen, and not in RC cell cultures. Even though
adipocytes were histologically undetectable in RC cultures not treated with BRL, RC cells expressed PPAR and
CCAAT/enhancer binding protein (C/EBP) mRNAs throughout osteoblast development and their expression was
increased by BRL. Some single cell-derived BRL-treated osteogenic RC colonies were stained not only with ALP/
von Kossa but also with oil red O and co-expressed the mature adipocyte marker adipsin and the mature
osteoblast marker OCN, as well as PPAR and C/EBP mRNAs.
Conclusion: The data show that there are clear differences in the capacity of BRL to alter the fate choices of
precursor cells in stromal (RBM) versus calvarial (RC) cell populations and that recruitment of adipocytes can
occur from multiple precursor cell pools (committed preadipocyte pool, multi-/bipotential osteo-adipoprogenitor
pool and conversion of osteoprogenitor cells or osteoblasts into adipocytes (transdifferentiation or plasticity)).
They also show that mechanisms beyond activation of PPARγ by its ligand are required for changing the fate of
committed osteoprogenitor cells and/or osteoblasts into adipocytes.
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Osteoblasts and adipocytes derive from a common mes-
enchymal progenitor and appear to display plasticity
between the phenotypes and an inverse relationship
between expression of the two lineages under certain
pathological and several experimental conditions [1]. For
example, a reciprocal relationship between marrow adi-
pocyte content and bone mass has been reported in oste-
oporosis [2]. Studies on the senescence-accelerated
(SAMP6) [3] and aging mouse [4] models also suggest
that osteoblastogenesis is decreased concomitant with an
increase in the number of marrow adipocytes.
As summarized previously [5], however, it can often be
difficult to interpret the developmental and cellular basis
of the inverse relationship between osteoblasts and adi-
pocytes, when both bi-/multipotential progenitors reside
in the same populations as restricted monopotential pro-
genitors that may display plasticity or transdifferentiation
capacity. Data from different approaches confirm multi-
ple possible cellular events underlying transitions
between the two lineages (see, e.g., [6,7]). Thus, the
number of adipocytes in bone marrow stromal or bone-
derived populations may reflect the frequency of commit-
ted adipocyte precursors (pathway 2), the conversion of
osteoprogenitor cells and/or osteoblasts into adipocytes
(pathway 3), and changes to the balance in commitment
choices of mesenchymal stem cells (pathway 1). Specific
treatments and different culture conditions including dif-
ferent cell densities may dependently or independently
affect any or all of these lineage choices.
Adipocyte differentiation is under the control of peroxi-
some proliferator-activated receptors (PPARs), members
of the nuclear receptor superfamily, in concert with mem-
bers of the CCAAT/enhancer-binding protein (C/EBP)
family of basic leucine zipper nuclear transcription factors
[8]. The analyses of homo- and heterozygous PPARγ-defi-
cient mice and ES cells have suggested that PPARγ may
positively and negatively determine the fate of osteo-adi-
pocyte precursors respectively at least during early differ-
entiation events [7]. The thiazolidinedione antidiabetic
agents, which are PPARγ-selective ligands, induce adipo-
genesis in a variety of culture models including mesenchy-
mal stem/stromal cells and cell lines (see, e.g., [9-12]).
However, different ligands of the thiazolidinedione class
with different capacities for PPARγ activation appear to
differentially modulate adipogenesis versus osteoblast-
ogenesis in the mouse model [12]. Taken together, these
reports suggest that PPARγ-selective ligands may induce
adipogenesis not only in mesenchymal stem or multipo-
tential progenitor cells (pathway 1), but also in osteopro-
genitors and/or osteoblasts (pathway 3).
Three members of the C/EBP family (C/EBPα, β, and δ)
have also been implicated in adipocyte differentiation [8].
Analyses of the differentiation program in adipocytic cell
lines and genetically altered mice have shown that C/EBP
and PPAR work sequentially and cooperatively to stimu-
late the molecular events required for adipogenesis. C/
EBPβ and δ also activate osteocalcin gene transcription
and synergize with runt-related transcription factor 2
(Runx2), a master regulator for osteoblastogenesis, at the
C/EBP element to regulate bone-specific expression [13].
To elucidate the contribution of recruitment from a com-
mitted osteoblast precursor pool (pathway 3) versus
multipotential progenitor pool (pathway 1) to adipogen-
esis induced by the PPARγ-selective ligand BRL-49653
(BRL), we compared primary cultures of fetal rat calvaria
(RC) cells (in which osteoblasts derive mainly from com-
mitted osteoprogenitors, a model of pathway 3, and in
which committed preadipocytes also reside, a model of
pathway 2) with rat bone marrow (RBM) cultures (repre-
senting a model of pathway 1) [1].
Results
The temporal sequence of osteoblast development in both
the RBM and RC cell culture models has been well-
described, and data support the concept that the models
reflect a preponderance of multi/bipotential progenitors
in the RBM system versus a preponderance of osteopro-
genitors in the RC cell system [1,14]. To determine
whether there is a difference in the effects of BRL on oste-
oblastogenesis between these two models, we first
assessed the number of bone nodules and adipocyte colo-
nies in RBM versus RC cell cultures treated with BRL (Fig.
1A and 1B). BRL increased the number of adipocyte colo-
nies formed in both culture models, while it markedly
decreased bone nodule formation in RBM but had no
detectable effect on bone nodule formation in RC cells
even at 10-fold higher concentrations (1.0 μM) than used
for RBM cultures. During bone nodule formation in both
RBM and RC cell cultures, the expected sequential marked
upregulation of osteoblast markers was seen, while adi-
pocyte markers remained relatively low and stable (Fig.
2A,B). In agreement with its effects on bone nodule/adi-
pocyte colony formation, BRL increased adipocyte marker
(lipoprotein lipase (LPL), fatty acid-binding protein
(aP2), and adipsin) and decreased osteoblast marker
(osteopontin (OPN), alkaline phosphatase (ALP), bone
sialoprotein (BSP), and osteocalcin (OCN)) mRNA levels
throughout the time course in RBM cultures (Fig. 2A,B).
Also consistent with the BRL-induced increase in adi-
pocyte colony number in RC cultures, expression of adi-
pocyte markers was increased by BRL treatment of RC cells
at all time points, but especially days 11 and 18 (Fig.
2A,B). Compared to the fetal adipose tissue control (Fig.
2C), expression levels of adipocyte markers are lower in
the BRL-treated RC and RBM cell cultures, but consistentPage 2 of 12
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cells in each case (adipose tissue>RBM>RC; see also Fig. 1)
and rosiglitazone effects in vivo[15]. On the other hand
and in parallel with the lack of effect of BRL on the
number of bone nodules formed (Fig. 1), osteoblast
marker mRNA levels were either unchanged or changed
only slightly by BRL at all doses tested, i.e., ALP and BSP
levels were slightly upregulated at day 11 (Fig. 2A,B).
Notably, expression of the mRNA for osteoblast master
regulator gene, Runx2, was not affected by BRL treatment
at any time in RC cell cultures (Fig. 2D).
To address whether the lack of suppression of osteoblast-
ogenesis by BRL in RC cell cultures was due to the absence
of its receptor, PPARγ, or other transcription factors
involved in the adipogenesis cascade, real-time PCR of the
PPAR and C/EBP family members was performed on RNA
from RC cells throughout the differentiation time course
(Fig. 3). Amongst molecules examined, C/EBPβ was
found only after robust amplification (41 cycles in regular
RT-PCR) and, even then, was not seen consistently in RC
samples (data not shown). On the other hand, PPAR
mRNAs as well as C/EBPα mRNAs were detected over the
time course of osteoblast development; PPARγ expression
decreased, while the expression of PPARα and C/EBPα
gradually increased, and PPARδ/β and C/EBPδ remained
unchanged. Amongst these transcription factors, PPARγ
and C/EBPα expression was significantly increased in
BRL-treated RC cells at all times tested (Fig. 3), raising the
possibility that BRL may convert at least some osteogenic
cells or their precursors towards an adipogenic pheno-
type.
Because RC cell cultures comprise a heterogeneous mix of
osteoprogenitor cell types at multiple differentiation
stages [16] as well as a small number of fibroblastic cells,
BRL exerts different effects on bone nodule and adipocyte colony formation in RBM versus RC cell culturesFigure 1
BRL exerts different effects on bone nodule and adipocyte colony formation in RBM versus RC cell cultures. 
Cells were fixed at day 17 (RBM) or day 18 (RC). A, Oil red O/von Kossa staining. B, The number of adipocyte colonies and 
bone nodules. BRL at 10 and 100 nM and 0.1 and 1.0 μM were used for RBM and RC cells, respectively. Data are mean ± SD of 
triplicate samples; results are representative of a minimum of three independent experiments. *p< 0.05 vs. vehicle.Page 3 of 12
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Expression of adipocyte and osteoblast markers is reciprocally affected by BRL in RBM but not in RC cellsFigure 2
Expression of adipocyte and osteoblast markers is reciprocally affected by BRL in RBM but not in RC cells. A 
Northern blot analysis of adipocyte and osteoblast markers; B Quantitative analysis by densitomtery. Adipocyte markers, LPL, 
aP2, and adipsin. Osteoblast markers, OPN, ALP, BSP, and OCN. RBM and RC cells were treated with BRL at 10 and 100 nM 
and 0.1 and 1.0 μM (indicated by increasing bar size), respectively, as shown in Fig. 1. Total RNA was harvested at appropriate 
days as indicated. C, RT-PCR analysis of LPL, adipsin and L32 in RC cell and RBM treated with BRL and in brown adipose tissue 
as a positive control. Samples of RC and RBM (in the presence of BRL at 1 μM and 100 nM, respectively) are the same as those 
in A. Adipo, brown adipose tissue from 21-day fetal rats. D, Real-time RT-PCR of Runx2 in RC cells treated with (+) and with-
out (-) 1 μM BRL. Samples are the same as those in A. L32, internal control. Data are mean ± SD of triplicate samples; results 
are representative of a minimum of three independent experiments.
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Expression profiling of PPARs and C/EBPs in the presence or absence of BRL during osteoblast development in RC cell culturesFigure 3
Expression profiling of PPARs and C/EBPs in the presence or absence of BRL during osteoblast development in 
RC cell cultures. Total RNA was collected as described in Fig. 2. Real-time RT-PCR was carried out by using specific primer 
sets for PPARα,γ, δ/β, C/EBPα, δ and L32. The ratio was calculated against the values of vehicle at day 5 that was set at 1.0. 
Data are mean ± SD of triplicate samples; results are representative of three independent experiments. *p< 0.05 vs. time-
matched values of vehicle.
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population [18], we next used a more discriminating
assay than total population analysis to address the ques-
tion of whether osteogenic cells can (trans)differentiate
into adipocytes when treated with BRL. We therefore
plated RC cells at very low density and analysed single
cell-derived isolated colonies (in this experiment, a total
of 732 colonies in 4 independent dishes (194 colonies at
day 11, 249 colonies at day 19 and 289 colonies at day
27); Fig. 4A shows a representative 100 mm dish plated at
low density for the colony forming unit (CFU) assay). We
confirmed that BRL treatment had no detectable effect on
the growth rate or total number of CFUs (Fig. 4B), ruling
out a generalized mitogenic or toxic effect of BRL in the
RC cell population. When we quantified the phenotypes
of individual colony types present, we found that BRL had
BRL increases adipocyte colonies without affecting osteoblastic colony formationFigure 4
BRL increases adipocyte colonies without affecting osteoblastic colony formation. RC cells plated at 500 cells/100 
mm dish were fixed at the days indicated and stained for adipogenesis (oil red O) and osteogenesis (ALP). A, Typical single cell 
colonies stained with ALP/von Kossa (day 27). B, Total number of CFU-F per 35-mm dish in the presence and absence of BRL 
at the concentrations indicated (day 27). C, The proportion of total colonies that are oil red O+ and/or ALP+ colonies in RC 
cells treated with and without BRL. Note that the proportion of the colonies showing a double (osteoblast plus adipocyte) 
phenotype increased with time. Data are mean ± SD of triplicate samples; results are representative of three independent 
experiments. *p< 0.05 vs. vehicle.Page 6 of 12
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osteoblastic phenotype (CFU-ALP), but induced oil red
O-single positive (adipocytic) as well as ALP/oil red O-
double positive (osteo–adipocytic) colonies. Note espe-
cially that many of the adipocyte colonies also contained
ALP-positive cells (Fig. 4C). The percentage of such dou-
ble-stained colonies increased over the time course of the
experiment, such that by the end of the experiment (day
27), a large number of oil red O-positive colonies induced
by BRL also had ALP-positive cells, suggesting that BRL
induced expression of both the osteoblast and adipocyte
developmental programs in some RC progenitor cells.
We next assessed adipocyte and osteoblast marker expres-
sion at day 33 in individual colonies with definitive oste-
oblast (cuboidal ALP-positive, ALP+ cells) or definitive
adipocyte (pleomorphic cells with patent lipid droplets)
or mixed (containing both cuboidal ALP+ and lipid-con-
taining cells) phenotypes as defined morphologically;
BRL induced a significant shift in colony type from single
ALP+ colonies to double ALP+/Oil red O+ colonies (p <
0.01). A representative agarose gel with amplimers
obtained by semiquantitative RT-PCR of RNA from 10
randomly selected colonies is shown in Fig. 5A: 3 ALP+
colonies (lanes 1–3) from vehicle-treated culture dishes,
and 6 ALP+ colonies (lanes 4–9) and 1 colony with typical
adipocyte morphology (oil red O+ lipid droplets; lane 10)
from BRL-treated culture dishes (Fig. 5A). Representative
results from quantification of osteo/adipocyte marker
mRNAs in 9 double ALP+/oil red O+ colonies in compari-
son to three ALP+ and three oil red O+ colonies are shown
in Fig. 5B. A summary of results from 68 randomly
selected colonies (9 of which were also oil red O+) and 25
ALP+ colonies from cultures grown in the presence or
absence of BRL respectively, and 3 oil red O+ colonies
from BRL-treated cultures) is shown in Table 1. Of the 25
ALP+ colonies formed in the absence of BRL, 22 colonies
expressed OCN, but none of them expressed adipsin; 10
of these also expressed PPARγ or C/EBPα and 7 colonies
expressed both (PPARγ+/C/EBPα+). The 3 adipocyte (Oil
red O+ colonies from the BRL-treated cultures expressed
adipsin, PPARγ and C/EBPα, but had no detectable OCN
expression. Of 40 ALP+ colonies formed in the presence of
BRL, 27 colonies expressed OCN, and 9 colonies co-
expressed OCN, adipsin and PPARγ and C/EBPα (Fig. 5B;
Table 1). BRL induced a significant shift in colony types
from ones expressing only one of PPARγ or C/EBPα to
ones expressing both factors (p < 0.05), and from ones
expressing OCN alone to those expressing both OCN and
adipsin, as well as PPARγ and C/EBPα (p < 0.01). Taken
together with the morphological assessment of colony
types, our results suggest that at least some osteoprogeni-
tor cells are induced by BRL to upregulate an adipogenic
differentiation program.
Discussion
Treatment of mouse or rat (RBM) stromal cell cultures
with BRL-49653 (BRL), a selective ligand for PPARγ, elicits
reciprocal effects on adipogenesis and osteoblastogenesis,
stimulating the former and inhibiting the latter, as
described [1-4]. In contrast, the ligand does not alter the
functional fate or endpoint of committed osteoprogeni-
tors resident in RC populations, i.e., formation of miner-
alized bone colonies is not altered, even though
adipogenesis is induced in this population. On the other
hand, some single cell-derived osteoblastic colonies in
BRL-treated but not untreated RC populations co-express
markers of both mature osteoblast and adipocyte. These
results suggest a clear difference in the progenitor status
between the two populations and support the conclusion
that BRL may show capacity to recruit adipocytes from
multiple precursor pools (Fig. 6).
It is worth considering that because RBM (from meso-
derm) and RC cells (from a mixture of neuroectoderm
and mesoderm) are embryologically distinct, the regula-
tion of fate selection by progenitors in the stromal versus
calvarial populations may be different. For example, some
hormones and growth factors regulate intramembranous
or periosteal bone formation (calvaria or periosteal
growth of other bones) differently than endosteal bone
formation (stromal cell-derived trabeculae and endosteal
growth) (e.g., parathyroid hormone effects; [19]). Thus,
RC and RBM cells may be subject to differential regulation
by activation of PPARγ (BRL), while responding similarly
to other factors, e.g., dexamethasone [1,5,14] and endog-
enous glucocorticoids as evidenced by 11β-hydroxyster-
oid dehydrogenase type 2-overexpressing mice driven by
α1(I)-collagen promoter [20].
Bone marrow stromal cell populations, often referred to
as mesenchymal stem cells, are capable of undergoing dif-
ferentiation along multiple mesenchymal lineages, but
are heterogeneous in the capacity of individual colonies
(CFU-F) to express multilineage versus more restricted
capacity (see, e.g., [21], and discussion in [1]). However,
the frequency of multipotential progenitors in stromal
populations appears quite high, e.g., ~30% of single cell-
derived colonies in human stroma [22] and >90% in a
recently-described alternative isolation/enrichment
method [21]. As described above, RC cell populations
also contain a mixture of cell lineages and types, e.g., oste-
oprogenitors and osteoblasts at different differentiation
stages, fibroblastic cells, adipocyte precursors [17], as well
as a multipotential side population [18]. However, the
frequency of functionally multipotential precursor or
stem cells, e.g., the RCJ3.1, clonally-derived multipoten-
tial cell line [23], bipotential adipo-osteoprogenitors [24]
or SP cells [18] appears to be very low in RC populations.
Additionally, RC populations contain preadipocytesPage 7 of 12
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genitor cells from bone marrow [27]. Our data support
the view that BRL induces differentiation/maturation of
adipocytes mainly from a committed preadipocyte pool
in RC populations. However, our data on single cell colo-
nies suggest that a subpopulation of committed osteopro-
genitors or relatively mature osteoblasts is also induced to
switch on the adipogenic pathway (pathway 3) when
PPARγ is activated, as we also recently proposed with
leukemia inhibitory factor treatments [26]. The expres-
sion of PPARγ and/or C/EBPs in some osteogenic cells in
our models and MC3T3-E1 cells [28] may also predispose
them to the pathway 3. It is also possible that at least some
of the osteo-adipogenic cells in BRL-treated RC popula-
tions represent recruitment from multipotential or bipo-
tential progenitor pools equivalent to those in stromal cell
Gene expression profiling of osteoblast and adipocyte markers in single cell-derived coloniesFigur  5
Gene expression profiling of osteoblast and adipocyte markers in single cell-derived colonies. Total RNA was 
obtained at day 33 from each randomly selected colony as shown in Fig. 4. A, A representative agarose gel with amplimers 
from RT-PCR for adipsin, BSP, OCN, PPARγ, and C/EBPα. L32, internal control. Samples shown in lanes 1–3 and lanes 4–9 
were collected from randomly selected ALP+ colonies in vehicle and BRL-treated cultures, respectively. One adipocyte colony 
(lane10) was also collected from a BRL-treated culture. B, Expression profiling of osteo/adipocyte marker mRNAs in ALP+/oil 
red O+ colonies in cultures treated with or without BRL. Data shown are from 9 ALP+/oil red O+ colonies; also shown for 
comparison are three ALP+ and three oil red O+ colonies. Data are representative of three independent experiments.Page 8 of 12
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lations would not be expected to markedly alter overall
osteoblast or adipocyte colony numbers (Fig. 4, 5A, and
see [14]), although we cannot discount the possibility that
activation of PPARγ dramatically changes their frequency.
In BRL-treated single cell colonies, mineralized colonies
with and without adipsin expression (Fig. 5B) correlated
with high and low levels of PPARγ respectively, which is
consistent with the hypothesis that RC cell populations
comprise two kinds or differentiation stages of progenitor
or osteoblastic cells as we described previously with
respect to glucocorticoid regulation [29,30], i.e., a sub-
population responsive to the PPARγ selective ligand and a
non-responsive subpopulation, with the former capable
of expressing both the adipocyte and osteoblast programs
and the latter expressing only the osteoblast program. Our
data are also consistent with the view that activation of
PPARγ alone by its ligand is not sufficient to induce com-
plete conversion of osteoprogenitor cells into adipocytes.
This view is consistent with an earlier report in which the
PPARγ selective ligand was unable to increase PPARγ
expression and cause adipocyte differentiation in human
adult trabecular-derived bone cells, although these cells
were able to undergo adipogenesis in the presence of iso-
butylmethylxanthine (IBMX) plus dexamethasone with
concomitant increase in expression of PPARγ [31]. Treat-
ment of MC3T3-E1 cells retrovirally overexpressing PPARγ
with insulin, dexamethasone and IBMX increases the adi-
pogenic capacity, which is further enhanced when C/
EBPα is co-overexpressed [32]. Together these data suggest
that mechanisms beyond activation of PPARγ by its ligand
(BRL) are required for changing the fate of committed
osteoprogenitor cells and/or osteoblasts into adipocytes.
BRL is a potent PPARγ-selective ligand but it is also known
to increase PPARγ expression [33], as it did in RC cells,
along with C/EBPα. These two transcription factors dis-
play interactive regulatory roles and cooperate to promote
adipocyte differentiation [34]. The role of these two fac-
tors, or other members of the families in osteoblasts has
been investigated recently (see e.g., [13]). Wnt/β-catenin
signaling suppresses C/EBPα and PPARγ, which shifts
mesenchymal cell fate toward osteoblastogenesis at the
expense of adipogenesis [35,36]. The lack of coordinate
expression of PPAPγ and C/EBPα during osteoblast differ-
entiation in our models suggests that they may not coop-
erate in osteoblast differentiation as they do in adipocyte
differentiation.
Conclusion
The present study showed clear differences in the capacity
of the PPARγ-selective ligand BRL-49653 to alter the fate
choices of precursor cells in stromal versus calvarial cell
populations and that recruitment of adipocytes can occur
from multiple precursor cell pools (committed preadi-
pocyte pool, multi-/bipotential osteo-adipoprogenitor
pool and conversion of osteoprogenitor cells or osteob-
lasts into adipocytes (transdifferentiation or plasticity)).
They also show that mechanisms beyond activation of
PPARγ by its ligand are required for changing the fate of
committed osteoprogenitor cells and/or osteoblasts into
adipocytes.




(Total) 25 % 43 % 68
CFU ALP+ 25 100 31 72 56
Oil red O+ 0 0 3 7 3
ALP+/Oil red O+ 0 0 9** 21 9
ALP-/Oil red O- 0 0 0 0 0
OCN+ 22 88 27 63 49
Adipsin+ 0 0 3 7 0
OCN+/Adipsin+ 0 0 9** 21 9
OCN-/Adipsin- 3 12 4 9 7
Gene expression PPARγ+ 4 16 3 7 7
C/EBPα+ 6 24 5 12 11
PPAR γ+/C/EBPα+ 7 28 31* 72 35
PPARγ-/C/EBPα- 8 32 4 9 12
OCN+/Adipsin+/PPARγ+/C/EBPα+ 0 0 9** 21 9
** p < 0.01 vs. no BRL; *p < 0.05 vs. no BRL.Page 9 of 12
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Cell cultures
Animal use and procedures were approved by the Univer-
sity of Toronto Animal Care Committee and Research
Facilities for Laboratory Animal Science, Natural Science
Center for Basic Research and Development, Hiroshima
University.
RBM stromal cell cultures
Bone marrow stromal cells from the femora of young
adult male Wistar rats (110–130 g) were cultured essen-
tially as described [37]. Briefly, femora were dissected and
immersed α-MEM with antibiotics. After removal of the
epiphysis, the marrow was collected by flushing MEM,
supplemented with antibiotics and 10% fetal calf serum
(FCS), through the shafts with a syringe. The resulting cell
suspension was plated into a T75-tissue culture flask and
incubated in the same medium supplemented addition-
ally with ascorbic acid (50 μg/ml) and dex (10 nM) (dif-
ferentiation medium) for a week at 37°C in a humidified
atmosphere of 95% air and 5% CO2. Cells were then har-
vested with trypsin and collagenase and subcultured at 0.2
× 104 cells/cm2 in differentiation medium; medium was
changed every 2–3 days until bone nodules were
observed. Cells were treated chronically with or without
BRL (10–100 nM). To promote mineralization, 10 mM β-
glycerophosphate was added for the last 5 days.
RC Cell Cultures
Cells were enzymatically isolated from calvariae of 21-d
Wistar rat fetuses by sequential digestion with collagenase
as described [38]. Cells obtained from the last four of five
digestion steps were grown in α-MEM containing 10%
FCS and antibiotics. After 24 h, cells were collected by
trypsinization, and cultured at the same cell density as
RBM in the presence or absence of BRL (0.1–1 μM) in dif-
ferentiation medium as above but without dex. To obtain
single cell colonies, RC cells were also cultured at very low
density (500 cells/100 mm dish) in differentiation
medium [16].
Possible cellular origin of adipocytes induced by BRLFigure 6
Possible cellular origin of adipocytes induced by BRL. The number of adipocytes may be influenced by a number of 
recruitment pathways, including from commitment of mesenchymal stem cells or bipotential progenitors to the preadipocyte 
pool (pathway 1), from maturation of committed adipocyte precursors (pathway 2) and the conversion of committed osteo-
progenitor cells and/or osteoblasts into adipocytes via transdifferentiation or plasticity (pathway 3). BRL directs mesenchymal 
stem or multipotential progenitor cells in RBM to adipocytes at the expense of osteoblast differentiation. A portion of osteo-
progenitor cells in RC cells may be able to express both osteoblast and adipocyte phenotypes in response to BRL. A portion of 
committed adipocyte precursors in RC populations also responds to BRL with an increase in adipogenesis.Page 10 of 12
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Total RNA was harvested at appropriate culture time
points with TRIzol reagent (Invitrogen, Carlsbad, CA)
according to the manufacturer's instructions. Twenty
micrograms of total RNA were electrophoresed on 1%
agarose-17% formaldehyde gels and transferred onto pos-
itively charged nylon membranes (Hybond-N+, GE
Healthcare, Buckinghamshire, UK). The membranes were
cross-linked, prehybridized and hybridized with specific
probes as described (see below, and [39]). After washing,
the membranes were exposed to X-ray film at -80°C for
various times. cDNAs for rat BSP (pBSP1), OCN (pOC9),
ALP and OPN were described previously [37]. The aP2
and adipsin cDNAs were cloned from BRL-treated mouse
bone marrow cells, using specific primers designed with
Primer Picking (Primer 3). The primer sequences were as
follows: aP2, 5'-ATA GCA CCC TCC TGT GCT G-3' and 5'-
CCA GCC TCT TCC TTT GCT C-3'; adipsin, 5'-TGT ACT
TCG TGG CTC TGG TG-3' and 5'-ATC CGG TAG GAT
GAC ACT CG-3'. A mouse LPL cDNA was purchased from
the American Type Culture Collection (63117; Rockville,
MD). All probes were labeled with [α32P]dCTP using a
Multiprime DNA labelling system (GE Healthcare). L32
was used as internal control.
Real-time and semiquantitative RT-PCR
cDNA was synthesized from 2 μg or less (100–400 ng
from single cell colonies) of total RNA isolated from cells
and tissues as above, using Superscript II (Invitrogen) or
RevatraAce (Toyobo, Osaka, Japan). The sequence of PCR
primers were designed using Primer 3; PPARα, 5'-CGA
CAA GTG TGA TCG AAG CTG CAA G-3' and 5'-GTT GAA
GTT CTT CAG GTA GGC TTC-3'; PPARδ/β, 5'-GGG CTG
ACG GCC AGC GAG GGA-3' and 5'-TGG GGA GAA CCG
GGT GCC GA-3'; PPARγ, 5'-GCG GAG ATC TCC AGT GAT
ATC-3' and 5'-TCA GCG ACT GGG ACT TTT CT-3'; BSP,
5'-CGC CTA CTT TTA TCC TCC TCT G-3' and 5'-CTG ACC
CTC GTA GCC TTC ATA G-3'; OCN, 5'-AGG ACC CTC
TCT CTG CTC AC-3'and 5'-AAC GGT GGT GCC ATA GAT
GC-3'; Runx2, 5'-CTT CAT TCG CCT CAC AAA C-3' and
5'-CAC GTC GCT CAT CTT GCC GG-3'; L32, 5'-CAT GGC
TGC CCT TCG GCC TC-3' and 5'-CAT TCT CTT CGC TGC
GTA GCC-3'. The primers for C/EBPα,β,δ, and adipsin
were as follows: C/EBPα, 5'-GAA TCT CCT AGT CCT GGC
TC-3' and 5'-GAT GAG AAC AGC AAC GAG TAC-3 [40];
C/EBPβ, 5'-GCC ACG GAC ACC TTC GAG G-3' and 5'-
CGG CTC CGC CTT GAG CTG-3' [40]; C/EBPδ, 5'-GCG
GAT CCG AGG TGA CAG CCC AAC TTG-3' and 5'-GGA
ATT CGG TCG TTC GGA GTC TCT AAG-3' [41]; adipsin,
5'-TGT ACT TCG TGG CTC TGG TG-3' and 5'-ATC CGG
TAG GAT GAC ACT CG-3' [42]. Real-time PCR was carried
out by using the LightCycler system (SYBR Green 1; Roche
Diagnostics, Indianapolis, IN) according to manufac-
turer's instructions. L32 was used as internal control. For
semiquantitative assessment of expression levels, each
PCR reaction was done over an increasing series of cycles
from 17 to 45 cycles and PCR products were size fraction-
ated on 1% ethidium bromide/agarose gels. A representa-
tive gel is shown in which the bands are visualized from
cycle number within the exponential phase of amplifica-
tion as determined by densitometric analysis of amplim-
ers (Image Quant software, MD Apps) (see for example,
[43]).
Staining
For lipid-containing adipocyte detection, cells were fixed
in 10% neutral buffered formalin and stained with oil red
O solution [11]. To detect osteoblasts, cells were incu-
bated with either single or double-stained for ALP and
mineral (2.5% silver nitrate (von Kossa)) as described
[39]. For single colony analyses, colonies were double-
stained with ALP and oil red O.
Statistics
Experiments were repeated on a minimum of three inde-
pendent cell isolates. In some cases, as specified in the fig-
ure legends, a representative experiment is shown in
which data points are the mean ± SD of triplicate samples.
Statistical significance was computed by ANOVA and
Dunnet's t-test and set at the level of p < 0.05 for high den-
sity cultures. For low density cultures, at least three inde-
pendent experiments were done; data were analyzed by
Fisher's exact test and significance was set at p < 0.05.
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